⨯

working

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers


Get Started
Already a member? Log in here

More Content

More Content

ReNeuron Group - H124 results reaffirm focus on CustomEX

Companies: ReNeuron Group plc

ReNeuron's retinal treatment 'appears to have sustained long-term beneficial effect'

Companies: ReNeuron Group plc

Steady performer

Companies: ReNeuron Group plc (RENE:LON)Redes Energeticas Nacionais SA (RENE:LIS)

ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating Huntington's disease

Companies: ReNeuron Group plc

Allenby Capita: ReNeuron Group - Interims & new data presented

Companies: ReNeuron Group plc

Copyright © 2023 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top